US2751324A - Antibiotic compositions comprising oxytetracycline and carbomycin - Google Patents

Antibiotic compositions comprising oxytetracycline and carbomycin Download PDF

Info

Publication number
US2751324A
US2751324A US299758A US29975852A US2751324A US 2751324 A US2751324 A US 2751324A US 299758 A US299758 A US 299758A US 29975852 A US29975852 A US 29975852A US 2751324 A US2751324 A US 2751324A
Authority
US
United States
Prior art keywords
oxytetracycline
carbomycin
antibiotic
compositions
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US299758A
Inventor
Arthur R English
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Priority to US299758A priority Critical patent/US2751324A/en
Application granted granted Critical
Publication of US2751324A publication Critical patent/US2751324A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D499/00Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • Oxytetracycline is a highly effective compound, especi ally useful in the treatment of infectious diseases.
  • Carbomycin has been shown to be effective against a variety of different microorganisms. This compound is described in detail and claimed by the name of antibiotic P. A. 97 in the copending patent application of Fred W. Tanner, Jr., et al., filed on February 7, 1952, under Serial No. 270,298. It has now been found that compositions containing a oxytetracycline antibiotic and a carbomycin antibiotic act in a synergistic manner against certain microorganisms which cause serious infections in vivo. In particular, these compositions are quite effective against Micrococci and streptococci, especially Micrccoccus pyogenes and Streptomyces faecalis.
  • compositions containing from approximately 5 to approximately 95 parts by weight of an oxytetracycline antibiotic, together with from about 95 to about 5 parts by weight of a carbomycin antibiotic exert the synergistic activity described above. It may be found that a particular organism is more susceptible to a certain formulation of these compositions than to others. For instance, one organism may be quite susceptible to a composition containing parts of carbomycin with 90 parts of oxytetracycline, whereas another may be considerably more susceptible to a composition containing equal amounts of each of the component antibiotics. A minimum of bacteriological testing is required to determine the most useful of these compositions for combating any particular organism.
  • compositions containing equal parts by weight of carbomycin and oxytetracycline, and a 10% carbomycin: oxytetracycline formulation also proved effective at the same level. The utility of the new products for disinfecting purposes and other in vitro applications is thus demonstrated.
  • Example 111 The effectiveness of compositions of carbomycin with oxytetracycline was tested in vitro against a strain of Micrococcus pyogenes var. aureus (Y-l) which had been found to be quite resistant to a variety of antibiotics. When oxytetracycline was tested alone against this microorganism, it was found that 50 micrograms were required per milliliter of medium to inhibit the organism. 2.5 micrograms of carbomycin hydrochloride per milliliter were required to inhibit this organism. However, a total of only 1.5 micrograms of a composition containing 75 by weight of carbomycin hydrochloride and 25% by weight of oxytetracycline hydrochloride per milliliter of medium was necessary to inhibit this resistant organism.
  • compositions containing 90% of the carbomycin salt and 10% of oxytetracycline hydrochloride were tested, it was found that a total concentration of the composition containing 1.50 micrograms/milliliter was also effective in inhibiting the growth of the resistant organism. It is apparent that low levels of oxytetracycline very definitely increase the activity of carbomycin against this organism, despite the fact that oxytetracycline of itself has a relatively low level of activity on this particular organism.
  • the novel compositions thus exhibit definite and unexpected synergism.
  • a bacteriologically active composition which comprises an oxytetracycline antibiotic and a carbomycin antibiotic.
  • a bacteriologically active composition which comprises a major proportion of an oxytetracycline antibiotic, together with a minor proportion of a carbomycin antibiotic.
  • composition according to claim 2 wherein each of the two antibiotic constituents is in the form of a salt.
  • a bacteriologcially active composition which com- 4 prises between 5 and 95 parts by weight of oxytetracycline hydrochloride, together with between 95 and 5 parts by weight of carbomycin hydrochloride.
  • Tanner et al. Some Properties of Magnamycin. Antibiotics and Chemotherapy, September 1952, p. 441.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

ANTIBIOTIC COMPOSITIONS COMPRISING OXY- TETRACYCLINE AND CARBOMYCIN Arthur R. English, Mineola, N. Y., assiguor to Chas. Pfizer & Co., Inc., Brooklyn, N. Y., a corporation of Delaware No Drawing. Application July 18, 1952, Serial No. 299,758
4 Claims. (Cl. 167-65) This application is concerned with certain antibiotic compositions. In particular, it is concerned with compositions of oxytetracycline (also known by the registered trademark Terramycin) and carbomycin.
Oxytetracycline is a highly effective compound, especi ally useful in the treatment of infectious diseases. Carbomycin has been shown to be effective against a variety of different microorganisms. This compound is described in detail and claimed by the name of antibiotic P. A. 97 in the copending patent application of Fred W. Tanner, Jr., et al., filed on February 7, 1952, under Serial No. 270,298. It has now been found that compositions containing a oxytetracycline antibiotic and a carbomycin antibiotic act in a synergistic manner against certain microorganisms which cause serious infections in vivo. In particular, these compositions are quite effective against Micrococci and streptococci, especially Micrccoccus pyogenes and Streptomyces faecalis.
In this application, where reference is made to an oxytetracycline antibiotic, the term is meant to include not only amphoteric oxytetracycline, but salts of oxytetracycline with acids, such as hydrochloric or sulfuric acids, and with metals such as sodium, as well as other known, biologically active forms of the antibiotic. Not only may pure amphoteric oxytetracycline and salts thereof be used, but also crude products recovered from fermentation broths, concentrates thereof, and the like. bomycin is a basic compound which forms salts such as the sulfate or the hydrochloride; and the phrase a carbomycin antibiotic as used herein denotes not only the base per se, but its various salts and other biologically active derivatives.
Compositions containing from approximately 5 to approximately 95 parts by weight of an oxytetracycline antibiotic, together with from about 95 to about 5 parts by weight of a carbomycin antibiotic, exert the synergistic activity described above. It may be found that a particular organism is more susceptible to a certain formulation of these compositions than to others. For instance, one organism may be quite susceptible to a composition containing parts of carbomycin with 90 parts of oxytetracycline, whereas another may be considerably more susceptible to a composition containing equal amounts of each of the component antibiotics. A minimum of bacteriological testing is required to determine the most useful of these compositions for combating any particular organism.
The compositions of this invention may be used in a variety of forms and manners, depending upon the particular microorganisms involved. Thus, the materials may be employed as disinfectants in vitro, or applied in vivo locally in forms of solutions, suspensions, powders, ointments and so forth. The compositions may also be injected intramuscularly for veterinary use in suitable media for such injections. For instance, a solution in saline or water may be employed. The oral administration of suitable preparations of the compositions of this invention may also be used for the treatment of certain nited States Patent O 2,751,324 Ce Patented June 19, 1956 2 diseases. The oral preparations may take the form of capsules, tablets, elixirs, or other dry or liquid prepara- Example I A composition was prepared containing 10% of pure, crystalline carbomycin and 90% crystalline oxytetracycline hydrochloride. milliliters of double strength standard bacteriological nutrient broth was placed in each of a number of test tubes. A portion of the antibiotic composition was added to each tube. This was followed by a 0.5-rnilliliter portion of a standard inoculum of Micrococcus pyogenes var. aureus. Finally. the volume of the mixture was diluted to 4 milliliters with sterile water. The tubes were incubated at 37 C. overnight and then were observed for evidence of growth of the microorganism as indicated by turbidity. From a series of such tests, all conducted under sterile conditions and to which varying amounts of the antibiotic composition Were added, there was determined the minimum concentration of the composition required to inhibit growth of the microorganism in question. It was found that with the particular composition tested a total of 0.30 microgram of the composition per milliliter of the mixture was effective. However, when either carbomycin or oxytetracycline hydrochloride was used alone, 0.50 microgram of the antibiotic per milliliter of medium was necessary to achieve the same inhibition. When a mixture containing 25% of carbomycin and of oxytetracycline was used, it was found that a total of 0.30 microgram of this composition was effective in inhibiting the growth of the organism. Compositions containing equal parts by weight of carbomycin and oxytetracycline, and a 10% carbomycin: oxytetracycline formulation also proved effective at the same level. The utility of the new products for disinfecting purposes and other in vitro applications is thus demonstrated.
by weight by weight of A sample of 2 Example 11 The effectiveness of compositions containing various proportions of amphoteric oxytetracycline and carbomycin base was tested in the same manner as in Example I against Streptococcus faecalis A121. Neither carbomycin nor oxytetracycline proved effective in inhibiting this organism at a level of 0.50 mcg./ml., whereas compositions of carbomycin with oxytetracycline ranging from 9 parts of oxytetracycline with 1 part of carbomycin to 1 oxytetracycline for 9 parts carbomycin, proved effective at levels of 0.30 microgram of the individual compositions per milliliter.
Example 111 The effectiveness of compositions of carbomycin with oxytetracycline was tested in vitro against a strain of Micrococcus pyogenes var. aureus (Y-l) which had been found to be quite resistant to a variety of antibiotics. When oxytetracycline was tested alone against this microorganism, it was found that 50 micrograms were required per milliliter of medium to inhibit the organism. 2.5 micrograms of carbomycin hydrochloride per milliliter were required to inhibit this organism. However, a total of only 1.5 micrograms of a composition containing 75 by weight of carbomycin hydrochloride and 25% by weight of oxytetracycline hydrochloride per milliliter of medium was necessary to inhibit this resistant organism. When a composition containing 90% of the carbomycin salt and 10% of oxytetracycline hydrochloride was tested, it was found that a total concentration of the composition containing 1.50 micrograms/milliliter was also effective in inhibiting the growth of the resistant organism. It is apparent that low levels of oxytetracycline very definitely increase the activity of carbomycin against this organism, despite the fact that oxytetracycline of itself has a relatively low level of activity on this particular organism. The novel compositions thus exhibit definite and unexpected synergism.
What is claimed is:
l. A bacteriologically active composition which comprises an oxytetracycline antibiotic and a carbomycin antibiotic.
2. A bacteriologically active composition which comprises a major proportion of an oxytetracycline antibiotic, together with a minor proportion of a carbomycin antibiotic.
3. A composition according to claim 2, wherein each of the two antibiotic constituents is in the form of a salt. 4. A bacteriologcially active composition which com- 4 prises between 5 and 95 parts by weight of oxytetracycline hydrochloride, together with between 95 and 5 parts by weight of carbomycin hydrochloride.
References Cited in the file of this patent Neter et al.: Synergistic eiiects of polymyxin B and terramycin on bacteria encountered in urinary tract infactions. J. Urol., 67(5):773775. 1952. Through Biol. Abstr., November 1952, p. 2807.
Tanner et al.: Some Properties of Magnamycin. Antibiotics and Chemotherapy, September 1952, p. 441.
Welch et al.: Bacterial Spectrum of Erythromycin, Carbomycin, Chloramphenicol, Aureomycin and Terramycin. Antibiotics and Chemotherapy, December 1952, pp. 693 to 696.
Hobby et al.: The tnberculostatic activity of terramycin." Am. Rev. Tubere., vol. 63, pp. 434 to 440, April 1951. Through Squibb Abstract Bulletin, vol. 24, No. 17, April 25, 1951, p. A-362.
Armstrong: Effect of Combinations of Antibiotics. J. Lab. and Clin. Med., vol. 37, April 1951, pp. 584 to

Claims (1)

1. A BACTERIOLOGICALLY ACTIVE COMPOSITION WHICH COMPRISES AN OXYTETRACYCLINE ANTIBIOTIC AND A CARBOMYCIN ANTIBIOTIC.
US299758A 1952-07-18 1952-07-18 Antibiotic compositions comprising oxytetracycline and carbomycin Expired - Lifetime US2751324A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US299758A US2751324A (en) 1952-07-18 1952-07-18 Antibiotic compositions comprising oxytetracycline and carbomycin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US299758A US2751324A (en) 1952-07-18 1952-07-18 Antibiotic compositions comprising oxytetracycline and carbomycin

Publications (1)

Publication Number Publication Date
US2751324A true US2751324A (en) 1956-06-19

Family

ID=23156162

Family Applications (1)

Application Number Title Priority Date Filing Date
US299758A Expired - Lifetime US2751324A (en) 1952-07-18 1952-07-18 Antibiotic compositions comprising oxytetracycline and carbomycin

Country Status (1)

Country Link
US (1) US2751324A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2899362A (en) * 1959-08-11 Hemostatic sponges and method of
US2945784A (en) * 1956-03-29 1960-07-19 Lepetit Spa Streptomycin and dihydrostreptomycin salts

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2899362A (en) * 1959-08-11 Hemostatic sponges and method of
US2945784A (en) * 1956-03-29 1960-07-19 Lepetit Spa Streptomycin and dihydrostreptomycin salts

Similar Documents

Publication Publication Date Title
Finland Emergence of antibiotic resistance in hospitals, 1935–1975
Waksman Streptomycin: background, isolation, properties, and utilization
Hyams et al. In vitro bactericidal effectiveness of four aminoglycoside antibiotics
Kirby Bacteriostatic and lytic actions of penicillin on sensitive and resistant staphylococci
Finland et al. Susceptibility of pneumococci and Haemophilus influenzae to antibacterial agents
Finland et al. Susceptibility of beta-hemolytic streptococci to 65 antibacterial agents
Staneck et al. Antimicrobial susceptibilities of anaerobic bacteria: recent clinical isolates
Zabransky et al. Bacteriostatic and bactericidal activities of various antibiotics against Bacteroides fragilis
Dornbusch et al. Antibiotic susceptibility of Clostridium species isolated from human infections
Waksman et al. Neomycin activity upon Mycobacterium tuberculosis and other Mycobacteria
US2751324A (en) Antibiotic compositions comprising oxytetracycline and carbomycin
Meyer et al. On penicillin
Hill Enhancement of experimental anaerobic infections by blood, hemoglobin, and hemostatic agents
Russell Synergism between sulphonamide drugs and antibiotics of the polymyxin group against Proteus sp. in vitro
Stokes et al. Antimicrobial action of pyocyanine, hemipyocyanine, pyocyanase, and tyrothricin
Waksman et al. The in vivo activity of neomycin
US3251738A (en) Anti-microbial potentiation with agents having plant hormone activity
Lawrence In vitro studies on the antibacterial actions of para-aminomethylbenzenesulfonamide derivatives
Hobby et al. Effect of Sulfonamides on Action of Penicillin
Leberman et al. Susceptibility of pleuropneumonia-like organisms to action of antibiotics: II. Terramycin and neomycin
Love Jr et al. Antibacterial action of tetracycline: comparisons with oxytetracycline and chlortetracycline.
Asmar et al. Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone
McDonald et al. Brief antibiotic exposure and effect on bacterial growth
Ebringer et al. Furan derivatives their common molecular denominator responsible for bleaching of Euglena gracilis
Höffler et al. Susceptibility of cutaneous propionibacteria to newer antibiotics